CONSISTENT EFFICACY

In 2 pivotal studies that included procedures ranging from low to high bleeding risk.1

Four Hot Air Balloons in the Sky Carrying Three Doptelet Platelet Characters

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter, randomized, double‐blind, placebo‐controlled studies (N=435)1,2

Doptelet Dosing Titration Chart for CLD

Primary endpoint: Proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following an elective procedure.1

Secondary endpoint: Proportion of patients who achieved platelet counts of >50x109/L on the day of procedure, and the change in platelet count from baseline to procedure day.1

  • Biliary interventions
  • Bronchoscopy +/- biopsy
  • Chemoembolization for HCC
  • Colonoscopy +/- polypectomy/biopsy
  • Dental procedures
  • Ethanol ablation
  • Laparoscopic interventions
  • Liver biopsy
  • Nephrostomy tube placement
  • Paracentesis
  • Radiofrequency ablation
  • Renal biopsy
  • Thoracentesis
  • Transjugular intrahepatic portosystemic shunt
  • Upper GI endoscopy +/- biopsy
  • Upper GI endoscopy +/- sclerotherapy
  • Upper GI endoscopy +/- variceal banding
  • Vascular catheterization

In the ADAPT studies, the percentage of patients who underwent procedures with low, moderate, or high risk was as follows: low 60.8%; moderate 17.2%; and high 22.1%.2

Doptelet Procedure Day High And Low Baseline Secondary Efficacy Graph

Primary endpoint: Patients not requiring a platelet transfusion or any rescue procedure for bleeding up to 7 days following a scheduled procedure.1

88%

of high-baseline patients taking Doptelet
achieved the primary endpoint (N=117).1

66%

of low-baseline patients taking Doptelet
achieved the primary endpoint (N=90).1

Mean platelet counts nearly doubled with Doptelet1

With Doptelet, platelet counts significantly increased by procedure day.1

UP TO

45,000

in high-baseline patients

AND

 

+32,000

in low-baseline patients1

97% of patients whose platelet counts were measured on procedure day had an increase with Doptelet.1,3†

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists. 

93%

of high-baseline patients reached the
50,000 platelets/μL target (N=58).1

69%

of low-baseline patients reached the
50,000 platelets/μL target (N=90).1

Doptelet Characters with Glasses and Hat

Explore the safety profile of Doptelet

Learn more about the pooled safety data from ADAPT-1 and ADAPT-2 studies.

VIEW SAFETY

PC=platelet count; R=randomized; qd=every day.

*From randomization of Doptelet 40 mg or Doptelet 60 mg once daily for 5 days up to 7 days after a procedure compared to placebo (P<0.0001; N=435).1

†270/277 patients treated with Doptelet in ADAPT-1 and ADAPT-2 had increased platelet counts by procedure day.1,3

  1. DOPTELET (avatrombopag) [prescribing information]. Durham, NC: AkaRx, Inc; 2021.
  2. Terrault N, Chen Y, Izumi N, et al. Avatrombopag before procedures reduces needs for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):718.
  3. Data on file. The SAS System. 2023: Sobi, Inc.